Loading patent…
AssigneeForschungsverbund Berlin E.V.
InventorsEnno Klussmann, Walter Rosenthal, Jorg Rademann, Frank Christian, Sina Meyer
Estimating the term…
The invention relates to non-peptidic molecules which modulate, especially inhibit, the interaction of protein kinase A (PKA) and A kinase anchor proteins (AKAP) and to a host or target organism that comprises said non-peptidic compounds or recognition molecules directed to said compounds, such as e.g. antibodies or chelating agents. The invention also relates to a pharmaceutical agent, especially for use in the treatment of diseases that are associated with a disturbance of the cAMP signal path, especially insipid diabetes, hypertonia, pancreatic diabetes, duodenal ulcer, asthma, heart failure, obesity, AIDS, edema, hepatic cirrhosis, schizophrenia and others. The invention also relates to the use of the inventive molecules.
Non-peptidic protein kinase A/protein kinase A anchor protein decouplers in accordance with Table A.
Non-peptidic protein kinase A/protein kinase A anchor protein decouplers having a molecular weight in the range of from 150 to 600 g/mol, preferably from 190 to 300 g/mol, a partition coefficient of log P≦10, preferably ≦8, with a maximum of 10 hydrogen bridge donors and a maximum of 10 hydrogen bridge acceptors, a solubility value log Sw of from −400 to 0, and a BrotN value of from 0 to 7.
(canceled)
(canceled)
Method for production of a medicament comprising the decoupler or a pharmaceutical agent comprising the decoupler for the prophylaxis or treatment of asthma, hypertonia, coronary heart diseases, hypertrophy of the heart, duodenal ulcer, heart failure, hepatic cirrhosis, schizophrenia, AIDS, pancreatic diabetes, insipid diabetes, obesity, chronic obstructive pulmonary diseases, and/or edemas.
The method according to claim 42, comprising formulating the substance into a pharmaceutically acceptable form.
Dependencies are inferred from the claim text.